- Home
- NBIX vs SF Comparison
NBIX vs SF Comparison
Compare NBIX & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- SF
- Stock Information
- Founded
- NBIX 1992
- SF 1890
- Country
- NBIX United States
- SF United States
- Employees
- NBIX N/A
- SF N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- SF Investment Bankers/Brokers/Service
- Sector
- NBIX Health Care
- SF Finance
- Exchange
- NBIX Nasdaq
- SF Nasdaq
- Market Cap
- NBIX 11.6B
- SF 12.0B
- IPO Year
- NBIX 1996
- SF N/A
- Fundamental
- Price
- NBIX $120.69
- SF $103.90
- Analyst Decision
- NBIX Buy
- SF Hold
- Analyst Count
- NBIX 21
- SF 8
- Target Price
- NBIX $168.35
- SF $117.71
- AVG Volume (30 Days)
- NBIX 1.6M
- SF 737.1K
- Earning Date
- NBIX 02-06-2025
- SF 01-29-2025
- Dividend Yield
- NBIX N/A
- SF 1.77%
- EPS Growth
- NBIX 33.20
- SF 46.03
- EPS
- NBIX 3.29
- SF 6.25
- Revenue
- NBIX $2,355,300,000.00
- SF $4,970,320,000.00
- Revenue This Year
- NBIX $16.29
- SF $15.10
- Revenue Next Year
- NBIX $16.90
- SF $9.19
- P/E Ratio
- NBIX $36.68
- SF $16.63
- Revenue Growth
- NBIX 24.81
- SF 14.95
- 52 Week Low
- NBIX $110.95
- SF $72.78
- 52 Week High
- NBIX $157.98
- SF $120.64
- Technical
- Relative Strength Index (RSI)
- NBIX 35.76
- SF 34.24
- Support Level
- NBIX $113.00
- SF $106.48
- Resistance Level
- NBIX $118.61
- SF $111.62
- Average True Range (ATR)
- NBIX 4.28
- SF 2.66
- MACD
- NBIX -2.22
- SF -0.88
- Stochastic Oscillator
- NBIX 18.81
- SF 7.56
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
About SF Stifel Financial Corporation
Stifel Financial is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 60% of the company's net revenue is derived from its global wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.